Active, not recruitingPhase 3NCT03652064

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Studying Infantile neuroaxonal dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Janssen Research & Development, LLC
Principal Investigator
Janssen Research & Development, LLC Clinical Trial
Janssen Research & Development, LLC
Intervention
Daratumumab(drug)
Enrollment
395 enrolled
Eligibility
18 years · All sexes
Timeline
20182026

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03652064 on ClinicalTrials.gov

Other trials for Infantile neuroaxonal dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Infantile neuroaxonal dystrophy

← Back to all trials